CANCER CENTER SUPPORT GRANT

这是一份五年竞争性续约的申请 21-26目前的NCI-Designated马约综合癌症中心。 在过去的四年里，马约基金会进行了重大投资 在癌症研究方面，随着新实验室空间的建设， 超过25位基础科学家和创造9个基础科学 研究机构的所有研究者都可获得核心。 扩大 在基础科学中，导致了四个新的基础科学的发展， 癌症中心的项目：癌症遗传学，生长因子，细胞 信号传导和基因调控。 这些项目包括25个 研究人员以前参加过前“免疫学”， “生物化学和分子生物学”课程以及30个新的 investigators. 临床试验和癌症药理学课程 也通过增加新的人员得到加强。 在 当前应用程序，需要支持九个核心：1）Admini- 统计和临床研究支持系统，3） 药学，4）病理学，5）细胞免疫学，6）药理学，7） 细胞遗传学，8）分子探针，和9）肽合成和 测序 肽合成和测序核心是新的。 一 病理学中增加了组织学制备功能 核心（原“组织分布”）。 增加发展资金是 要求支持基础广泛的发展中癌症控制， 预防计划，放射肿瘤学的发展计划，一个国家- 最先进的共聚焦显微镜/亚细胞操作核心，以及 流行病学核心，以支持未来的控制和新的 癌症遗传学项目 第一年要求的直接费用总额为 一百八十六万

This is an application for a five-year competitive renewal for years 21-26 of the present NCI-Designated Mayo Comprehensive Cancer Center. Over the past four years, the Mayo Foundation has made a major investment in cancer research with construction of new laboratory space, recruitment of more than 25 basic scientists. and the creation of 9 basic science cores available to all investigators at the Institution. The expansion in basic science has led to the development of four new basic science programs in the Cancer Center: Cancer Genetics, Growth Factors, Cell Signalling, and Gene Regulation. These programs include the 25 investigators previously-participating in the former "Immunology" and "Biochemistry and Molecular Biology" programs as well as 30 new investigators. The programs in Clinical Trials and Cancer Pharmacology have also been strengthened by the addition of new personnel. In the current application, support is requested for nine cores: 1) Admini- stration, 2) Statistical and Clinical Research Support Systems, 3) Pharmacy, 4) Pathology, 5) Cellular Immunology , 6) Pharmacology, 7) Cytogenetics, 8) Molecular Probes, and 9) Peptide Synthesis and Sequencing. The Peptide Synthesis and Sequencing core is new. A capability for histologic preparation has been added to the Pathology Core (formerly "Tissue Distribution"). Increased developmental funds are requested to support a broadly based developing cancer control and prevention program, a developing program in radiation oncology, a state- of-the-art confocal microscopy/subcellular manipulation core, and an epidemiology core to support future programs in control and the new program in cancer genetics. Total direct costs requested in year 1 are $1.86 million.